Symbols / EVGN
EVGN Chart
About
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop Novel Therapies for for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.71M |
| Enterprise Value | 9.98M | Income | -10.69M | Sales | 8.02M |
| Book/sh | 0.13 | Cash/sh | 1.83 | Dividend Yield | — |
| Payout | 0.00% | Employees | 117 | IPO | — |
| P/E | — | Forward P/E | -0.62 | PEG | — |
| P/S | 0.96 | P/B | 6.40 | P/C | — |
| EV/EBITDA | -0.69 | EV/Sales | 1.25 | Quick Ratio | 4.41 |
| Current Ratio | 5.11 | Debt/Eq | 14.61 | LT Debt/Eq | — |
| EPS (ttm) | -1.10 | EPS next Y | -1.35 | EPS Growth | — |
| Revenue Growth | -82.60% | Earnings | 2026-03-05 | ROA | -30.60% |
| ROE | -70.63% | ROIC | — | Gross Margin | 65.01% |
| Oper. Margin | -8.73% | Profit Margin | -34.29% | Shs Outstand | 8.72M |
| Shs Float | 8.63M | Short Float | 0.86% | Short Ratio | 1.74 |
| Short Interest | — | 52W High | 2.42 | 52W Low | 0.81 |
| Beta | 1.18 | Avg Volume | 443.70K | Volume | 64.03K |
| Target Price | $2.50 | Recom | None | Prev Close | $0.81 |
| Price | $0.84 | Change | 3.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.50
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-50.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
$2.50
High
$2.50
Mean
$2.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-22 | main | Lake Street | Buy → Buy | $4 |
| 2024-08-23 | main | Lake Street | Buy → Buy | $12 |
| 2023-10-02 | init | Alliance Global Partners | — → Buy | $2 |
| 2023-08-18 | main | Lake Street | Buy → Buy | $3 |
| 2023-07-21 | main | Roth MKM | Buy → Buy | $6 |
| 2023-05-02 | init | Lake Street | — → Buy | $2 |
| 2022-09-12 | main | Aegis Capital | — → Buy | $8 |
| 2022-09-02 | main | Roth MKM | Buy → Buy | $3 |
| 2021-10-08 | init | Roth Capital | — → Buy | $7 |
| 2021-07-29 | init | Aegis Capital | — → Buy | $10 |
| 2020-12-01 | init | Cantor Fitzgerald | — → Overweight | $9 |
- Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan ue, 10 Feb 2026 08
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - PR Newswire ue, 10 Feb 2026 08
- New AI-led push targets lung cancers that resist chemo and drugs - Stock Titan ue, 17 Feb 2026 13
- Evogene stock soars after licensing deal for cancer therapeutic - Investing.com Wed, 04 Feb 2026 08
- Evogene Enters Warrant Inducement Agreement Amid Stock Decline - Intellectia AI ue, 10 Feb 2026 08
- Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks Wed, 11 Feb 2026 08
- Why did EVGN shares drop more than 14% today? - MSN ue, 10 Feb 2026 20
- EVGN Stock Rising: Excitement or Caution? - StocksToTrade Mon, 21 Apr 2025 07
- Evogene stock rises as company expands Google Cloud collaboration By Investing.com - Investing.com Nigeria ue, 10 Feb 2026 15
- How Evogene and Google Cloud use AI agents to speed drug and crop discovery - Stock Titan ue, 10 Feb 2026 08
- Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - ChartMill ue, 10 Feb 2026 08
- Leading drug discovery scientists join Evogene's AI engine push - Stock Titan Mon, 09 Feb 2026 08
- EVGN’s Financial Rollercoaster: When Gains Become Losses - StocksToTrade ue, 10 Jun 2025 07
- Experimental gut bacteria therapy targets kidney and lung cancer - Stock Titan Wed, 04 Feb 2026 08
- AI-designed drugs take aim at inflammatory diseases affecting millions - Stock Titan Wed, 11 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 872.85K | -576.52 | -592.48K | 181.93K |
| TaxRateForCalcs | 0.23 | 0.00 | 0.23 | 0.23 |
| NormalizedEBITDA | -19.27M | -22.81M | -24.43M | -28.67M |
| TotalUnusualItems | 3.79M | -454.00K | -2.58M | 791.00K |
| TotalUnusualItemsExcludingGoodwill | 3.79M | -454.00K | -2.58M | 791.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.48M | -23.88M | -26.64M | -27.79M |
| ReconciledDepreciation | 2.50M | 2.61M | 2.58M | 2.23M |
| ReconciledCostOfRevenue | 2.68M | 1.69M | 909.00K | 767.00K |
| EBITDA | -15.48M | -23.26M | -27.01M | -27.88M |
| EBIT | -17.98M | -25.87M | -29.59M | -30.12M |
| NetInterestIncome | 409.00K | 975.00K | -237.00K | -270.00K |
| InterestExpense | 63.00K | 115.00K | 165.00K | 315.00K |
| InterestIncome | 957.00K | 1.25M | 182.00K | 291.00K |
| NormalizedIncome | -19.41M | -23.43M | -24.65M | -28.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.48M | -23.88M | -26.64M | -27.79M |
| TotalExpenses | 30.72M | 32.15M | 28.62M | 31.88M |
| TotalOperatingIncomeAsReported | -22.21M | -26.51M | -26.94M | -30.95M |
| DilutedAverageShares | 5.70M | 4.57M | 4.12M | 4.04M |
| BasicAverageShares | 5.70M | 4.57M | 4.12M | 4.04M |
| DilutedEPS | -2.89 | -5.20 | -6.50 | -6.90 |
| BasicEPS | -2.89 | -5.20 | -6.50 | -6.90 |
| DilutedNIAvailtoComStockholders | -16.48M | -23.88M | -26.64M | -27.79M |
| NetIncomeCommonStockholders | -16.48M | -23.88M | -26.64M | -27.79M |
| NetIncome | -16.48M | -23.88M | -26.64M | -27.79M |
| MinorityInterests | 1.57M | 2.08M | 3.21M | 2.65M |
| NetIncomeIncludingNoncontrollingInterests | -18.05M | -25.95M | -29.84M | -30.45M |
| NetIncomeContinuousOperations | -18.05M | -25.95M | -29.84M | -30.45M |
| TaxProvision | 9.00K | -33.00K | 90.00K | 13.00K |
| PretaxIncome | -18.05M | -25.99M | -29.75M | -30.43M |
| OtherIncomeExpense | 3.76M | -454.00K | -2.58M | 791.00K |
| EarningsFromEquityInterest | -39.00K | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 3.79M | -454.00K | -2.58M | 791.00K |
| NetNonOperatingInterestIncomeExpense | 409.00K | 975.00K | -237.00K | -270.00K |
| TotalOtherFinanceCost | 485.00K | 158.00K | 254.00K | 246.00K |
| InterestExpenseNonOperating | 63.00K | 115.00K | 165.00K | 315.00K |
| InterestIncomeNonOperating | 957.00K | 1.25M | 182.00K | 291.00K |
| OperatingIncome | -22.21M | -26.51M | -26.94M | -30.95M |
| OperatingExpense | 28.04M | 30.46M | 27.71M | 31.12M |
| OtherOperatingExpenses | 524.00K | -3.50M | ||
| ResearchAndDevelopment | 16.65M | 20.78M | 20.79M | 21.12M |
| SellingGeneralAndAdministration | 10.87M | 9.68M | 10.41M | 9.99M |
| SellingAndMarketingExpense | 822.00K | 1.01M | 1.01M | 653.00K |
| GeneralAndAdministrativeExpense | 10.04M | 8.67M | 9.40M | 9.34M |
| OtherGandA | 3.79M | 2.66M | 3.40M | 3.79M |
| SalariesAndWages | 6.25M | 6.01M | 6.00M | 5.55M |
| GrossProfit | 5.83M | 3.95M | 766.00K | 163.00K |
| CostOfRevenue | 2.68M | 1.69M | 909.00K | 767.00K |
| TotalRevenue | 8.51M | 5.64M | 1.68M | 930.00K |
| OperatingRevenue | 8.51M | 5.64M | 1.68M | 930.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.51M | 5.06M | 4.13M | 4.12M |
| ShareIssued | 6.51M | 5.06M | 4.13M | 4.12M |
| TotalDebt | 12.87M | 11.51M | 11.93M | 2.67M |
| TangibleBookValue | -13.65M | -1.12M | 13.79M | 38.45M |
| InvestedCapital | 8.92M | 22.42M | 38.04M | 53.65M |
| WorkingCapital | 2.89M | 27.52M | 32.13M | 50.01M |
| NetTangibleAssets | -13.65M | -1.12M | 13.79M | 38.45M |
| CapitalLeaseObligations | 2.50M | 1.14M | 1.82M | 2.67M |
| CommonStockEquity | -1.45M | 12.05M | 27.93M | 53.65M |
| TotalCapitalization | -1.45M | 22.42M | 38.04M | 53.65M |
| TotalEquityGrossMinorityInterest | 14.84M | 28.68M | 34.79M | 63.42M |
| MinorityInterest | 16.29M | 16.63M | 6.86M | 9.77M |
| StockholdersEquity | -1.45M | 12.05M | 27.93M | 53.65M |
| RetainedEarnings | -274.07M | -257.59M | -233.71M | -207.07M |
| AdditionalPaidInCapital | 272.26M | 269.35M | 261.40M | 260.49M |
| CapitalStock | 363.00K | 286.00K | 235.00K | 234.00K |
| CommonStock | 363.00K | 286.00K | 235.00K | 234.00K |
| TotalLiabilitiesNetMinorityInterest | 25.03M | 22.42M | 21.34M | 12.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.33M | 15.47M | 15.71M | 6.00M |
| NonCurrentDeferredLiabilities | 4.42M | 4.82M | 4.67M | 4.31M |
| NonCurrentDeferredRevenue | 4.33M | 4.43M | 4.67M | 4.31M |
| LongTermDebtAndCapitalLeaseObligation | 1.91M | 10.65M | 11.05M | 1.70M |
| LongTermCapitalLeaseObligation | 1.91M | 285.00K | 932.00K | 1.70M |
| LongTermDebt | 10.37M | 10.11M | ||
| CurrentLiabilities | 18.70M | 6.94M | 5.62M | 6.88M |
| OtherCurrentLiabilities | 2.88M | |||
| CurrentDeferredLiabilities | 683.00K | 750.00K | 101.00K | 264.00K |
| CurrentDeferredRevenue | 683.00K | 750.00K | 101.00K | 264.00K |
| CurrentDebtAndCapitalLeaseObligation | 10.96M | 853.00K | 884.00K | 974.00K |
| CurrentCapitalLeaseObligation | 589.00K | 853.00K | 884.00K | 974.00K |
| CurrentDebt | 10.37M | |||
| OtherCurrentBorrowings | 10.37M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.54M | 1.99M | 2.66M | |
| PayablesAndAccruedExpenses | 4.18M | 5.34M | 4.64M | 5.64M |
| CurrentAccruedExpenses | 1.87M | 2.54M | 1.99M | 2.66M |
| Payables | 2.31M | 2.80M | 2.65M | 2.98M |
| OtherPayable | 1.08M | 1.02M | 1.62M | 1.52M |
| AccountsPayable | 1.23M | 1.78M | 1.04M | 1.46M |
| TotalAssets | 39.86M | 51.10M | 56.13M | 76.30M |
| TotalNonCurrentAssets | 18.27M | 16.63M | 18.38M | 19.41M |
| NonCurrentPrepaidAssets | 12.00K | 28.00K | 74.00K | 25.00K |
| NonCurrentDeferredAssets | 1.74M | 0.00 | 94.00K | 0.00 |
| NonCurrentDeferredTaxesAssets | 1.74M | 0.00 | 94.00K | 0.00 |
| NonCurrentAccountsReceivable | 74.00K | 25.00K | ||
| InvestmentsAndAdvances | 82.00K | 0.00 | ||
| LongTermEquityInvestment | 82.00K | 0.00 | ||
| InvestmentsinAssociatesatCost | 82.00K | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 12.20M | 13.17M | 14.14M | 15.21M |
| OtherIntangibleAssets | 12.20M | 13.17M | 14.14M | 15.21M |
| NetPPE | 4.25M | 3.44M | 4.07M | 4.18M |
| AccumulatedDepreciation | -20.95M | -22.56M | -21.02M | -19.63M |
| GrossPPE | 25.20M | 26.00M | 25.08M | 23.81M |
| Leases | 16.19M | 17.59M | 17.39M | 16.95M |
| OtherProperties | 5.43M | 4.99M | 4.66M | 4.26M |
| MachineryFurnitureEquipment | 3.58M | 3.42M | 3.04M | 2.60M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 21.59M | 34.47M | 37.75M | 56.89M |
| CurrentDeferredAssets | 1.30M | 0.00 | ||
| RestrictedCash | 0.00 | 32.00K | 77.00K | |
| PrepaidAssets | 1.67M | 2.53M | 995.00K | 1.68M |
| Inventory | 1.82M | 76.00K | 566.00K | 92.00K |
| Receivables | 1.49M | 804.00K | 803.00K | 1.17M |
| OtherReceivables | 396.00K | 447.00K | 455.00K | 886.00K |
| AccruedInterestReceivable | 1.62M | 0.00 | 7.00K | |
| AccountsReceivable | 1.09M | 357.00K | 348.00K | 281.00K |
| CashCashEquivalentsAndShortTermInvestments | 15.31M | 31.06M | 35.35M | 53.87M |
| OtherShortTermInvestments | 10.00K | 10.29M | 6.38M | 21.54M |
| CashAndCashEquivalents | 15.30M | 20.77M | 28.98M | 32.33M |
| CashFinancial | 15.30M | 20.77M | 28.98M | 32.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.33M | -22.36M | -24.85M | -25.56M |
| RepaymentOfDebt | -901.00K | -836.00K | -803.00K | -580.00K |
| IssuanceOfDebt | 0.00 | 10.00M | 0.00 | |
| IssuanceOfCapitalStock | 123.00K | 8.45M | 21.00K | 29.58M |
| CapitalExpenditure | -626.00K | -785.00K | -1.17M | -847.00K |
| EndCashPosition | 15.30M | 20.77M | 28.98M | 32.33M |
| BeginningCashPosition | 20.77M | 28.98M | 32.33M | 46.23M |
| EffectOfExchangeRateChanges | -49.00K | -245.00K | -2.28M | 1.10M |
| ChangesInCash | -5.42M | -7.96M | -1.06M | -15.01M |
| FinancingCashFlow | 4.66M | 18.15M | 9.34M | 30.28M |
| CashFlowFromContinuingFinancingActivities | 4.66M | 18.15M | 9.34M | 30.28M |
| NetOtherFinancingCharges | -66.00K | 10.54M | 10.12M | 790.00K |
| ProceedsFromStockOptionExercised | 5.50M | 0.00 | 7.00K | 484.00K |
| NetCommonStockIssuance | 123.00K | 8.45M | 21.00K | 29.58M |
| CommonStockIssuance | 123.00K | 8.45M | 21.00K | 29.58M |
| NetIssuancePaymentsOfDebt | -901.00K | -836.00K | -803.00K | -580.00K |
| NetLongTermDebtIssuance | -901.00K | -836.00K | -803.00K | -580.00K |
| LongTermDebtPayments | -901.00K | -836.00K | -803.00K | -580.00K |
| LongTermDebtIssuance | 0.00 | 10.00M | 0.00 | |
| InvestingCashFlow | 9.62M | -4.54M | 13.27M | -20.57M |
| CashFlowFromContinuingInvestingActivities | 9.62M | -4.54M | 13.27M | -20.57M |
| NetInvestmentPurchaseAndSale | 10.19M | -3.78M | 14.45M | -19.72M |
| SaleOfInvestment | 27.34M | 15.92M | 15.36M | 4.39M |
| PurchaseOfInvestment | -17.15M | -19.70M | -911.00K | -24.11M |
| NetPPEPurchaseAndSale | -568.00K | -759.00K | -1.17M | -847.00K |
| SaleOfPPE | 58.00K | 26.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -626.00K | -785.00K | -1.17M | -847.00K |
| OperatingCashFlow | -19.70M | -21.58M | -23.68M | -24.72M |
| CashFlowFromContinuingOperatingActivities | -19.70M | -21.58M | -23.68M | -24.72M |
| TaxesRefundPaid | -11.00K | -31.00K | -40.00K | -13.00K |
| InterestReceivedCFO | 934.00K | 905.00K | 186.00K | 297.00K |
| InterestPaidCFO | -67.00K | -115.00K | -165.00K | -315.00K |
| ChangeInWorkingCapital | -3.31M | -400.00K | -771.00K | 1.66M |
| ChangeInOtherWorkingCapital | -559.00K | -194.00K | -247.00K | 128.00K |
| ChangeInPayablesAndAccruedExpense | -1.20M | 758.00K | -1.10M | 1.04M |
| ChangeInAccruedExpense | -668.00K | 550.00K | -675.00K | 127.00K |
| ChangeInPayable | -534.00K | 208.00K | -421.00K | 915.00K |
| ChangeInAccountPayable | -596.00K | 742.00K | -469.00K | 625.00K |
| ChangeInPrepaidAssets | -16.00K | |||
| ChangeInInventory | -1.74M | 490.00K | -474.00K | -92.00K |
| ChangeInReceivables | 191.00K | -1.45M | 1.05M | 578.00K |
| ChangesInAccountReceivables | -734.00K | -9.00K | -67.00K | -59.00K |
| OtherNonCashItems | -686.00K | -412.00K | 3.10M | -873.00K |
| StockBasedCompensation | 1.79M | 1.88M | 1.19M | 2.61M |
| DeferredTax | 9.00K | -33.00K | 90.00K | 13.00K |
| DeferredIncomeTax | 9.00K | -33.00K | 90.00K | 13.00K |
| DepreciationAmortizationDepletion | 2.50M | 2.61M | 2.58M | 2.23M |
| DepreciationAndAmortization | 2.50M | 2.61M | 2.58M | 2.23M |
| AmortizationCashFlow | 974.00K | 971.00K | 1.07M | 932.00K |
| AmortizationOfIntangibles | 974.00K | 971.00K | 1.07M | 932.00K |
| Depreciation | 1.53M | 1.64M | 1.51M | 1.30M |
| OperatingGainsLosses | -2.81M | -26.00K | 121.00K | |
| EarningsLossesFromEquityInvestments | 39.00K | 0.00 | 0.00 | |
| GainLossOnInvestmentSecurities | -3.37M | |||
| GainLossOnSaleOfPPE | 524.00K | -26.00K | 0.00 | 121.00K |
| NetIncomeFromContinuingOperations | -18.05M | -25.95M | -29.84M | -30.45M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EVGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|